Emergent Biosolutions INC

Emergent BioSolutions announced a $52.7 million contract modification from the U.S. government for its ACAM2000 smallpox and mpox vaccine.

Emergent BioSolutions reported Q1 2026 total revenues of $156.1 million, exceeding the high end of its guidance range.

Emergent BioSolutions Inc. reported the outcomes of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of key proposals.

Emergent BioSolutions Inc. announced the appointment of John D. Fowler, Jr., a veteran in healthcare and financial services, to its Board of Directors, effective March 1, 2026.

Emergent BioSolutions Inc. reported significant progress in its multi-year turnaround strategy for 2025, achieving strong adjusted EBITDA and improved operating margins, while providing a cautious outlook for 2026 with anticipated declines in profitability.

Emergent BioSolutions presents its multi-year transformation plan, highlighting significant debt reduction, improved profitability, and strategic growth initiatives at the J.P. Morgan Healthcare Conference.

Emergent BioSolutions reported a significant increase in operating income for the nine months ended September 30, 2025, driven by cost reductions and strategic divestitures, despite a decline in overall revenue.

Emergent BioSolutions Inc. reported a significant turnaround to net income and positive cash flow in Q2 2025, driven by cost reductions and strategic divestitures, despite a decline in total revenues.

Emergent BioSolutions announces its Q1 2025 financial results, highlighting increased net income and strategic moves including the sale of the Baltimore-Bayview facility and a new share repurchase program.

Emergent BioSolutions reports a net income of $114.8 million for Q3 2024, a significant turnaround from a net loss of $263.4 million in the same period last year, driven by increased MCM product sales and strategic divestitures.

Emergent BioSolutions reported a net loss of $274.1 million for the second quarter of 2024, impacted by restructuring charges and declining product sales, while also navigating significant debt and going concern issues.

Emergent BioSolutions saw a significant increase in revenue in the first quarter of 2024, driven by strong sales of MCM products and NARCAN, while also navigating ongoing restructuring efforts and financial challenges.

Emergent BioSolutions Inc. reported a net income of $52.6 million in 2025, a significant turnaround from prior year losses, despite a 29% decrease in total revenues.

Emergent BioSolutions details its FY2024 financial performance, strategic restructuring, and sets sights on a turnaround in 2025 with a focus on core products and international expansion.

Emergent BioSolutions has adopted a new compensation recovery policy and released its full year 2023 financial results, including a strategic shift in its business focus.

Emergent BioSolutions SVP, Products Business Paul Anthony Williams reported a sale of 3,000 common shares on July 1, 2026, executed under a pre-arranged 10b5-1 trading plan.

Paul Anthony Williams, SVP of Products Business at Emergent BioSolutions Inc., reported a transaction involving the withholding of shares to cover tax obligations.

Richard S. Lindahl, EVP and CFO of Emergent BioSolutions Inc., reported a transaction involving the withholding of shares to cover taxes related to restricted stock units.

Coleen Glessner, EVP at Emergent BioSolutions, reported a transaction involving the withholding of shares to cover taxes related to restricted stock units.

William Hartzel, SVP of Bioservices at Emergent BioSolutions Inc., reported a transaction involving the sale of 1,741 shares of common stock.

Emergent BioSolutions Director Sujata Tyagi Dayal reports transactions involving restricted stock units and stock options, including sales to cover tax obligations.

Emergent BioSolutions announces its 2026 annual meeting of stockholders, detailing director elections, auditor ratification, executive compensation, and a critical proposal to increase shares for its stock incentive plan.

Emergent BioSolutions Inc. is holding its 2025 Annual Meeting on April 30, 2025, and stockholders are encouraged to vote on key proposals.

Emergent BioSolutions' 2025 proxy statement highlights the company's efforts to stabilize its financials, turnaround the business, and transform for sustainable stockholder value, while detailing executive compensation and corporate governance practices.

Emergent BioSolutions Inc. will hold its annual stockholder meeting on May 23, 2024, to vote on key proposals including the election of directors, ratification of the company's accounting firm, executive compensation, and an amendment to the stock incentive plan.

Emergent BioSolutions will hold its 2024 annual meeting of stockholders virtually on May 23, 2024, to vote on director elections, ratification of the accounting firm, executive compensation, and an amendment to the stock incentive plan.

Emergent BioSolutions Inc. has filed a registration statement to allow the sale of over 3.6 million shares and 2.5 million warrants by lenders who recently provided a $250 million term loan to the company.

Emergent BioSolutions has filed a registration statement for the resale of up to 3,613,338 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock by selling securityholders.

Vanguard Capital Management has reported a 4.92% ownership stake in Emergent BioSolutions Inc., holding 2,540,945 shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 9.0% in Emergent BioSolutions Inc. as of June 30, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.04% beneficial ownership stake in Emergent BioSolutions Inc.

Dimensional Fund Advisors LP has disclosed a beneficial ownership of 5.3% of Emergent BioSolutions Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Emergent BioSolutions Inc. following an internal realignment.

State Street Corporation has reported a 5.1% beneficial ownership stake in Emergent BioSolutions Inc., holding 2,696,375 shares of common stock.